The biosimilar/noninnovator sector of the endocrinology market is evolving. Eli Lilly/Boehringer Ingelheim’s Abasaglar/Basaglar was the first biosimilar/noninnovator insulin glargine to launch in Europe and the United States. Subsequently, the EC has approved Biocon/Mylan’s insulin glargine biosimilar, Semglee, and more recently, Sanofi has launched Admelog, the first insulin lispro biosimilar to be available in the United States.
The prescribing behavior of endocrinologists will directly impact the uptake of these products, including insulin brands such as Sanofi’s Lantus and Eli Lilly’s Humalog. Understanding physicians’ attitude and behavior toward biosimilars is critical for development and marketing strategies aimed at persuading endocrinologists to prescribe and drive biosimilar/noninnovator uptake.
DRG’s primary research with endocrinologists in the United States, France, and Germany allows us to assess the dynamics determining current and future biosimilar/noninnovator uptake within the endocrinology space.
This report includes the following topics:
- Physicians’ current experience and familiarity with biosimilars.
- Current levels of biosimilar prescribing.
- Main drivers and barriers influencing biosimilar uptake.
- Impact of cost and clinical data on biosimilar uptake.
Markets covered: United States, France, and Germany.
Primary research: Online quantitative survey of 91 endocrinologists.